Zobrazeno 1 - 10
of 21
pro vyhledávání: '"K R, Zasadny"'
Autor:
Michael F. Clarke, K. R. Zasadny, H B Grossman, I R Francis, Richard L. Wahl, Yoshifumi Sugawara
Publikováno v:
Radiology. 211:249-256
To evaluate the feasibility of positron emission tomography (PET) with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with germ cell tumor (GCT) to monitor treatment and differentiate residual masses after chemotherapy.Twenty-six FDG PET
Publikováno v:
IEEE Transactions on Nuclear Science. 37:642-646
Quantitative Anger camera tomography requires correction for Compton scattering. The Anger camera spectral-fitting technique can measure scatter fractions at designated positions in an image, allowing for correction. To permit verification of those m
Publikováno v:
1995 IEEE Nuclear Science Symposium and Medical Imaging Conference Record.
The implementation of spectral analysis techniques involves solving a highly underdetermined linear system equation and is prone to the effect of measurement noise. The authors propose to use a regularized non-negative least-square estimator to stabi
Autor:
K F, Koral, Y, Dewaraja, J, Li, C L, Barrett, D D, Regan, K R, Zasadny, S G, Rommelfanger, I R, Francis, M S, Kaminski, R L, Wahl
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(9)
A study of the use of 131I-labeled anti-B1 monoclonal antibody, proceeded by an unlabeled predose, for therapy of previously untreated non-Hodgkin's lymphoma patients has recently been completed at the University of Michigan, Ann Arbor. More than hal
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(6)
131I-anti-B1 (CD20) radioimmunotherapy (RIT) is a promising approach for treatment of non-Hodgkin's lymphoma (NHL). We assessed the tumor metabolic response to RIT using FDG PET.We examined 14 patients with NHL, who were given first a tracer dose of
Autor:
K F, Koral, J, Li, Y, Dewaraja, C L, Barrett, D D, Regan, K R, Zasadny, S G, Rommelfanger, I R, Francis, M S, Kaminski, R L, Wahl
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
In patients with non-Hodgkin's lymphoma being treated by I-131-radiolabeled anti-B1 monoclonal antibody, we test the hypothesis that the activity taken up in tumors during therapy is the same as that observed during tracer evaluation, except for scal
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 40(9)
Using PET, we investigated the change in 18F-fluorordeoxyglucose (FDG) uptake in the spleen after granulocyte colony-stimulating factor (G-CSF) treatment.Forty-two FDG PET scans in 12 patients with locally advanced breast cancer who received G-CSF tr
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 39
The purpose of this article is to describe the methods used to determine the precise, patient-specific dose (in mCi) of 131I anti-B1 antibody needed to deliver a specified whole-body radiation dose (generally 75 cGy) to patients being treated for non
Autor:
R L, Wahl, K R, Zasadny, D, MacFarlane, I R, Francis, C W, Ross, J, Estes, S, Fisher, D, Regan, S, Kroll, M S, Kaminski
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 39
Iodine-131 anti-B1 antibody radioimmunotherapy for B-cell lymphoma was previously reported to have substantial antitumor activity in B-cell non-Hodgkin's lymphoma (NHL) after failures of standard and salvage chemotherapy. In this article, the Univers
Autor:
Susan J. Fisher, K. R. Zasadny, Denise Regan, S. D. Glenn, Charles W. Ross, A. W. Milik, Mark S. Kaminski, I R Francis, Richard L. Wahl, Missy Tuck, M. C. Fenner, Judith Estes
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 14(7)
PURPOSE The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting,